Phenominer Database Results (28 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Method Notes Clinical Measurement Notes Experiment Notes Record ID Study ID
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 328.0 nmol/l 41.0 123.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107303 3073
SHRSP/A3NCrl cardiac output controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 10 80.0 ml/min 5.0 15.81 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 106999 3073
SHRSP/A3NCrl stroke volume controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 6 222000.0 ml 19000.0 46540.31 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 107030 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 9 0.05 umol/l 0.01 0.02 tissue force analysis utilizing a force transducer 0.0 0 microMolar 107080 3073
SHRSP/A3NCrl end-systolic volume controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 10 98000.0 ml 10000.0 31622.78 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 106974 3073
SHRSP/A3NCrl heart left ventricle weight to body weight ratio controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. heart left ventricle mass male 134 days-141 days 10 2.82 mg/g 0.07 0.22 transthoracic echocardiography 0.0 0 3-5 cardiac cycles LV mass calculated from 2-D images with area-length method 107037 3073
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 6 460.0 nmol/l 83.0 203.31 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107302 3073
SHRSP/A3NCrl end-diastolic volume controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 6 0.33 ml 0.03 0.07 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 106967 3073
SHRSP/A3NCrl cardiac output controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 6 76.0 ml/min 7.0 17.15 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 106998 3073
SHRSP/A3NCrl heart left ventricle weight to body weight ratio controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. heart left ventricle mass male 134 days-141 days 6 2.69 mg/g 0.08 0.2 transthoracic echocardiography 0.0 0 3-5 cardiac cycles LV mass calculated from 2-D images with area-length method 107036 3073
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 6 98.0 % 5.0 12.25 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107091 3073
SHRSP/A3NCrl body weight controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. body mass male 134 days-141 days 6 331.0 g 16.0 39.19 body weighing method 0.0 0 HSFD +0.1 mg/kg/day GSK2181236A 106959 3073
SHRSP/A3NCrl end-diastolic volume controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 10 0.33 ml 0.02 0.07 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 106968 3073
SHRSP/A3NCrl mean arterial blood pressure controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. arterial blood pressure trait male 99 days-141 days 9 serial mean 183.0 mmHg 7.0 21.0 vascular indwelling catheter method femoral artery 432000.0 0 10 seconds every 5 minutes for 24hr high salt high fat diet +8 wk treat group baseline and after treatment 107049 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 6 0.25 10E-7mol/l 0.07 0.17 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107085 3073
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 6 54.0 % 6.0 14.7 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107295 3073
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 112.0 % 3.0 9.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107092 3073
SHRSP/A3NCrl ejection fraction controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 10 71.0 % 1.0 3.16 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 107025 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 6 88.0 % 6.0 14.7 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107073 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 0.26 10E-7mol/l 0.1 0.3 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107086 3073
SHRSP/A3NCrl end-systolic volume controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 6 110000.0 ml 11000.0 26944.39 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 106973 3073
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 67.0 % 6.0 18.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107296 3073
SHRSP/A3NCrl body weight controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. body mass male 134 days-141 days 10 338.0 g 5.0 15.81 body weighing method 0.0 0 HSFD +1.0 mg/kg/day GSK2181236A 106962 3073
SHRSP/A3NCrl ejection fraction controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 6 67.0 % 2.0 4.9 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 107024 3073
SHRSP/A3NCrl stroke volume controlled sodium chloride content drinking water (1 %) (for 49 days) and controlled fat content diet (24.5 %) (for 49 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 42 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. cardiac output trait male 134 days-141 days 10 234000.0 ml 14000.0 44271.89 transthoracic echocardiography 0.0 0 3-5 cardiac cycles 107031 3073
SHRSP/A3NCrl ratio of survivors to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. life span trait male 141 days-148 days 8 69.0 % Kaplan-Meier estimate 0.0 0 107042 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 9 89.0 % 7.0 21.0 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107074 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 6 0.05 umol/l 0.01 0.02 tissue force analysis utilizing a force transducer 0.0 0 microMolar 107079 3073